SG Americas Securities LLC Takes $436,000 Position in Kura Oncology, Inc. (NASDAQ:KURA)

SG Americas Securities LLC bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 50,039 shares of the company’s stock, valued at approximately $436,000. SG Americas Securities LLC owned approximately 0.06% of Kura Oncology as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC acquired a new position in shares of Kura Oncology in the 3rd quarter worth $25,000. Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology during the third quarter valued at approximately $146,000. Erste Asset Management GmbH purchased a new stake in shares of Kura Oncology in the 3rd quarter valued at approximately $215,000. Bellevue Group AG boosted its stake in Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after purchasing an additional 3,600 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Kura Oncology during the 3rd quarter valued at $268,000.

Kura Oncology Trading Down 1.5 %

Shares of KURA stock opened at $7.91 on Monday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12 month low of $6.98 and a 12 month high of $24.17. The business’s 50 day moving average is $8.97 and its two-hundred day moving average is $15.38. The company has a market cap of $615.11 million, a PE ratio of -3.35 and a beta of 0.81.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same period last year, the business posted ($0.50) EPS. Equities analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Activity at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,255 shares of company stock valued at $100,739 in the last three months. Corporate insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on KURA shares. UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. HC Wainwright boosted their price objective on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Bank of America lowered their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.38.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.